乳腺癌的靶向治疗

P. Kaur, A. Chauhan, Gajender Singh, S. Kataria
{"title":"乳腺癌的靶向治疗","authors":"P. Kaur, A. Chauhan, Gajender Singh, S. Kataria","doi":"10.5580/745","DOIUrl":null,"url":null,"abstract":"One of the oldest molecular target approaches in breast cancer is the targeting of the estrogen receptor with tamoxifen which is responsible for improvement in outcome, reduced the risk of new primary breast cancer and improves survival. Targeted therapies are now a component of treatment for many including colorectal, lung, and pancreatic cancers, as well as lymphoma, leukemia, and multiple myeloma.Recent identification of specific molecular target in cancer cells, leads to development of new targeted therapeutic approach, signal transduction, angiogenesis, and more recent approaches are induction of apoptosis or inhibition of antiapoptosis which offer the possibility of improving outcome for patient with early as well as metastatic breast cancer. This review discusses target therapies for HER family, angiogenesis and signal transduction. Abbreviations: HER -human epidermal growth factor receptor, VEGFvascular growth factor receptor, TKItyrosine kinase inhibitor, EGFRepidermal growth factor receptor, mTOR mammalian target of rapamycin, PSTprimary systemic chemotherapy, ER – oestrogen receptor, CDKcyclin-dependent kinase,PI3K-phosphatidyl-inositol3kinase.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"5 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting Therapies in the Management of Breast Carcinoma\",\"authors\":\"P. Kaur, A. Chauhan, Gajender Singh, S. Kataria\",\"doi\":\"10.5580/745\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"One of the oldest molecular target approaches in breast cancer is the targeting of the estrogen receptor with tamoxifen which is responsible for improvement in outcome, reduced the risk of new primary breast cancer and improves survival. Targeted therapies are now a component of treatment for many including colorectal, lung, and pancreatic cancers, as well as lymphoma, leukemia, and multiple myeloma.Recent identification of specific molecular target in cancer cells, leads to development of new targeted therapeutic approach, signal transduction, angiogenesis, and more recent approaches are induction of apoptosis or inhibition of antiapoptosis which offer the possibility of improving outcome for patient with early as well as metastatic breast cancer. This review discusses target therapies for HER family, angiogenesis and signal transduction. Abbreviations: HER -human epidermal growth factor receptor, VEGFvascular growth factor receptor, TKItyrosine kinase inhibitor, EGFRepidermal growth factor receptor, mTOR mammalian target of rapamycin, PSTprimary systemic chemotherapy, ER – oestrogen receptor, CDKcyclin-dependent kinase,PI3K-phosphatidyl-inositol3kinase.\",\"PeriodicalId\":22534,\"journal\":{\"name\":\"The Internet Journal of Oncology\",\"volume\":\"5 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Internet Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5580/745\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/745","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

最古老的乳腺癌分子靶标方法之一是用他莫昔芬靶向雌激素受体,这有助于改善结果,降低新发原发性乳腺癌的风险,提高生存率。靶向治疗现在是治疗许多癌症的一个组成部分,包括结肠直肠癌、肺癌和胰腺癌,以及淋巴瘤、白血病和多发性骨髓瘤。最近对癌细胞中特定分子靶点的识别,导致了新的靶向治疗方法的发展,信号转导,血管生成,以及最近的方法是诱导细胞凋亡或抑制抗细胞凋亡,这为早期和转移性乳腺癌患者提供了改善预后的可能性。本文就HER家族的靶向治疗、血管生成和信号转导进行综述。简称:HER -人表皮生长因子受体,vegf -血管生长因子受体,TKItyrosine激酶抑制剂,EGFRepidermal生长因子受体,mTOR哺乳动物雷帕霉素靶点,PSTprimary全身化疗,ER -雌激素受体,cdkcyclin依赖性激酶,pi3k -磷脂酰肌醇激酶。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Targeting Therapies in the Management of Breast Carcinoma
One of the oldest molecular target approaches in breast cancer is the targeting of the estrogen receptor with tamoxifen which is responsible for improvement in outcome, reduced the risk of new primary breast cancer and improves survival. Targeted therapies are now a component of treatment for many including colorectal, lung, and pancreatic cancers, as well as lymphoma, leukemia, and multiple myeloma.Recent identification of specific molecular target in cancer cells, leads to development of new targeted therapeutic approach, signal transduction, angiogenesis, and more recent approaches are induction of apoptosis or inhibition of antiapoptosis which offer the possibility of improving outcome for patient with early as well as metastatic breast cancer. This review discusses target therapies for HER family, angiogenesis and signal transduction. Abbreviations: HER -human epidermal growth factor receptor, VEGFvascular growth factor receptor, TKItyrosine kinase inhibitor, EGFRepidermal growth factor receptor, mTOR mammalian target of rapamycin, PSTprimary systemic chemotherapy, ER – oestrogen receptor, CDKcyclin-dependent kinase,PI3K-phosphatidyl-inositol3kinase.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信